First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis
This is a very early study, often called a 'first-in-human' trial, to test a new medicine named REGN20423. The main goal is to find out if it's safe for people to take and to understand how it behaves in the body. The study will include healthy adults as well as adults who have atopic dermatitis, which is a common type of eczema. By giving the medicine to both groups, researchers can learn a lot about its early effects. This type of research is crucial for developing new treatments for conditions like eczema, and it helps ensure that new medicines are carefully checked before they can be studied in larger groups of people.
At a glance
What is this study about?
This study is a very important first step in testing a new potential medicine called REGN20423. It's known as a 'first-in-human' study, meaning it's the very first time this particular drug will be given to people. The main reasons for doing this kind of study are to see if the medicine is safe and to understand how the body handles it. This involves looking at how much of the medicine stays in the body, how it's broken down, and how it leaves the body.
The study will involve two main groups of people: healthy adults and adults who have atopic dermatitis. Atopic dermatitis is a long-lasting skin condition that causes itchy and inflamed patches of skin. By studying both groups, researchers can gather important information about how the medicine affects different individuals.
Finding new ways to treat conditions like atopic dermatitis is really important because existing treatments don't work for everyone. Studies like this one are essential for working out if new medicines have the potential to eventually help people live better with their conditions. It's a careful and slow process to make sure new treatments are developed safely.
Key takeaways
- This is an early study of a new medicine for eczema (atopic dermatitis).
- It's the first time this medicine is being given to people to check its safety.
- Both healthy adults and adults with eczema can take part.
- Participation involves clinic visits and medical checks.
- You can stop participating at any time if you change your mind.
Who may be eligible?
To join this study, you need to be an adult, aged 18 or older. Both men and women are welcome to take part. The study is looking for healthy adults, as well as adults who have atopic dermatitis (a type of eczema).
If you have atopic dermatitis, the researchers will check your specific type and severity of eczema to make sure it matches what they are looking for in the study. Don't worry if you're not sure, the study team will ask you questions and do some checks to see if you're a good fit.
There will be other specific health requirements, like certain medical conditions you shouldn't have, or medications you shouldn't be taking. These are in place to keep participants safe and make sure the study results are clear. The study team will explain all of these to you in full detail.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you a healthy adult, or do you have atopic dermatitis (eczema)?
- Are you able to attend appointments at a study clinic?
- Do you understand that this is a first-time human study?
What does participation involve?
Taking part in this study would involve several visits to the clinic over a period of time. You would receive the study medicine, REGN20423, which would be given to you by the study team. They will carefully monitor you during and after you take the medicine to see how your body reacts.
Throughout the study, you would have various assessments, which might include blood tests, urine tests, and physical examinations. For those with eczema, there would also be assessments of your skin condition. These tests help the researchers understand how the medicine is working and check for any side effects. You'll have regular follow-up appointments to ensure your well-being. The total length of your participation would be explained in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is atopic dermatitis?
Atopic dermatitis is a common type of eczema that makes your skin dry, itchy, and irritated. It often appears as red patches and can sometimes be quite uncomfortable.
What does 'first-in-human' mean?
It means this is the very first time this new medicine is being given to people. It's a crucial early step to check its safety and how it works in the body.
Will I get better if I join this study?
Because this is such an early study, we can't promise you'll get better. The main goal is to learn about the new medicine's safety and how it works, not primarily to treat your condition at this stage.
Who can join this study?
Adults aged 18 or over can join. The study is looking for both healthy adults and adults who have atopic dermatitis.
Can I stop participating if I change my mind?
Yes, you can leave the study at any time, for any reason, without it affecting your usual healthcare.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.